The Get Data Out programme routinely publishes cancer statistics produced by NHS D (previously PHE) in a consistent table, called the Get Data Out (GDO) table. This table collects patients into groups with common characteristics, and then publishes information such as incidence, treatment rates, survival and Routes to Diagnosis for these groups.

This document sets out the definitions of the cohort and groups for Get Data Out tables for the 2023 release of data on soft tissue and peripheral nerve cancers between 2013 and 2020.

Soft tissue and peripheral nerve cancer cohort

The cohort of soft tissue and peripheral nerve cancers used by Get Data Out is defined in ICD-10/O-2 as all tumours coded to C47, C48 (all morphologies for male patients, and female patients with morphology 8693, 8800, 8801, 8802, 8803, 8804, 8805, 8806, 8963, 8990, 8991, 9040, 9041, 9042, 9043, 9044, 8810, 8811 – 8921, 9120 – 9373, 9490, 9500 or 9530 – 9582 only), and C49.

This cohort differs from the subgroup of “Soft tissue sarcomas” within the Get Data Out Sarcoma cohort in that this group of soft tissue and peripheral nerve cancer cases is defined primarily in terms of ICD-10 site, rather than morphology. It includes only tumours coded to C47, C48 and C49, and includes some tumours which are not sarcomas, including tumours with non-specific morphology codes. It does not include sarcomas found at other topographical sites.

Tumours arising in female patients coded to C48 with morphologies other than those listed above are considered likely to be ovarian-type tumours, and are included in the Ovary, fallopian tube and primary peritoneal carcinomas group of tumours and not in this cohort. Therefore, tumours coded to C48 included in this cohort are likely to be sarcomas.

This group is not split any further, annual figures only will be produced for this group.